Effect of tumor necrosis factor alpha and transforming growth factor beta 1 on plasminogen activator inhibitor-1 secretion from subcutaneous and omental human fat cells in suspension culture

Kissebah, 1994, Regional adiposity and morbidity, Physiol Rev, 74, 761, 10.1152/physrev.1994.74.4.761 Juhan-Vague, 1997, PAI-1, obesity, insulin resistance and risk of cardiovascular events, Thromb Haemost, 78, 656, 10.1055/s-0038-1657607 Hekman, 1988, Kinetic analysis of the interactions between plasminogen activator inhibitor 1 and both urokinase and tissue plasminogen activator, Arch Biochem Biophys, 2625, 199, 10.1016/0003-9861(88)90182-8 Wiman, 1984, Inactivation of tissue plasminogen activator in plasma. Demonstration of a complex with a new rapid inhibitor, J Biol Chem, 259, 3644, 10.1016/S0021-9258(17)43143-7 McGill, 1994, Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients, Diabetes, 43, 104, 10.2337/diabetes.43.1.104 De Pergola, 1997, Lower androgenicity is associated with higher plasma levels of prothrombotic factors irrespective of age, obesity, body fat distribution, and related metabolic parameters in men, Metabolism, 46, 1287, 10.1016/S0026-0495(97)90232-8 De Pergola, 1997, Increase in both pro-thrombotic and anti-thrombotic factors in obese premenopausal women: Relationship with body fat distribution, Int J Obes Relat Metab Disord, 21, 527, 10.1038/sj.ijo.0800435 Janand-Delenne, 1998, Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women, Int J Obes Relat Metab Disord, 22, 312, 10.1038/sj.ijo.0800585 Vague, 1986, Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects, Metabolism, 35, 250, 10.1016/0026-0495(86)90209-X Vague, 1989, Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women, Metabolism, 38, 913, 10.1016/0026-0495(89)90241-2 Gray, 1997, Proinsulin-like molecules and plasminogen activator inhibitor type 1 (PAI-1) activity in diabetic and non-diabetic subjects with and without myocardial infarction, Atherosclerosis, 130, 171, 10.1016/S0021-9150(96)06070-4 Juhan-Vague, 1996, Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris, Circulation, 94, 2057, 10.1161/01.CIR.94.9.2057 Sawdey, 1991, Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-α, and transforming growth factor-β, J Clin Invest, 88, 1346, 10.1172/JCI115440 Schneider, 1991, Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type 1: Implications for vascular disease in hyperinsulinemic states, 88, 9959 Schneider, 1993, Attenuated fibrinolysis and accelerated atherogenesis in type II diabetic patients, Diabetes, 42, 1, 10.2337/diabetes.42.1.1 van Hingsberg, 1988, Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo, Blood, 72, 1467, 10.1182/blood.V72.5.1467.1467 Shimomura, 1996, Enhanced expression of PAI-1 in visceral fat: Possible contributor to vascular disease in obesity, Nat Med, 2, 800, 10.1038/nm0796-800 Samad, 1996, Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-α and lipopolysaccharide, J Clin Invest, 97, 37, 10.1172/JCI118404 Samad, 1997, Elevated expression of transforming growth factor-β in adipose tissue from obese mice, Mol Med, 3, 37, 10.1007/BF03401666 Alessi, 1997, Production of plasminogen activator inhibitor 1 by human adipose tissue. Possible link between visceral fat accumulation and vascular disease, Diabetes, 46, 860, 10.2337/diabetes.46.5.860 Eriksson, 1998, Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals, Diabetologia, 41, 65, 10.1007/s001250050868 Hotamisligil, 1993, Adipose expression of tumor necrosis factor-α: Direct role in obesity-linked insulin resistance, Science, 259, 87, 10.1126/science.7678183 Cigolini, 1999, Expression of plasminogen activator inhibitor-1 in human adipose tissue: A role for TNF-α?, Atherosclerosis, 143, 81, 10.1016/S0021-9150(98)00281-0 Fearns, 1997, Induction of plasminogen activator inhibitor 1 gene expression in murine liver by lipopolysaccharide. Cellular localization and role of endogenous tumor necrosis factor-α, Am J Pathol, 150, 579 Rodbell, 1964, Metabolism of isolated fat cell. I. Effects of hormones on glucose metabolism and lipolysis, J Biol Chem, 239, 375, 10.1016/S0021-9258(18)51687-2 Chomczynski, 1987, Single-step method for isolation by acid guanidinium thiocyanate-phenol-chloroform extraction, Anal Biochem, 162, 156, 10.1016/0003-2697(87)90021-2 Wabitsch, 1996, Insulin and cortisol promote leptin production in cultured human fat cells, Diabetes, 45, 1435, 10.2337/diabetes.45.10.1435 Loskutoff, 1998, The adipocytes and hemostatic balance in obesity. Studies of PAI-1, Arterioscler Thromb Vasc Biol, 18, 1, 10.1161/01.ATV.18.1.1 Hekman, 1985, Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants, J Biol Chem, 260, 11581, 10.1016/S0021-9258(17)39071-3 Nordt, 1994, Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential risk factor for cardiovascular disease, Circulation, 89, 321, 10.1161/01.CIR.89.1.321 Velasquez, 1997, Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1. Lipoprotein(a) and immunoreactive insulin levels in patients with polycystic ovary syndrome, Metabolism, 46, 454, 10.1016/S0026-0495(97)90066-4 Glueck, 1999, Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with polycystic ovary syndrome, Metabolism, 48, 511, 10.1016/S0026-0495(99)90113-0 Lundgren, 1996, Elaboration of type-1 plasminogen activator inhibitor from adipocytes. A potential pathogenic link between obesity and cardiovascular disease, Circulation, 93, 106, 10.1161/01.CIR.93.1.106